Genolution
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Genolution makes diagnostic tools that detect genetic material, such as DNA and RNA, from human samples like blood, urine, and swabs, enabling laboratories to identify infectious diseases, cancers, and hereditary conditions.
Its products include reagents that extract nucleic acids from samples and automated instruments that perform that extraction, supplied to clinical and research settings. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company runs two distinct business lines: molecular diagnostics devices and products and services related to RNAi (RNA interference, a gene-silencing research technique).
Summary is AI-generated and may contain errors · figures from DART filings
Genolution in five facts
What does Genolution do?
Genolution makes diagnostic tools that detect genetic material, such as DNA and RNA, from human samples like blood, urine, and swabs, enabling laboratories to identify infectious diseases, cancers, and hereditary conditions.
Where is Genolution listed and in which sector?
Genolution (Korean name: 제놀루션) trades under KRX code 225220 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Genolution?
Its market capitalisation was US$21.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Genolution's latest annual revenue and operating profit?
For fiscal year 2025, Genolution reported revenue of US$7.1M, an operating loss of US$6.5M and a net loss of US$9.5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 31.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 16
- Report on securities held by executives/major shareholdersOct 16
- Report on securities held by executives/major shareholdersOct 2
- Report on securities held by executives/major shareholdersSep 18
- Report on securities held by executives/major shareholdersSep 18
- Report on securities held by executives/major shareholdersSep 8
- Report on large shareholdings (5% rule) (standard)Sep 1
- Treasury share disposal: results report
Genolution Co., Ltd. disposed of 88,122 treasury common shares to employees on August 25, 2026 at US$1.01 per share (total US$89K), leaving 1,024,784 treasury common shares (5.34% of shares outstanding) after the disposal.
Treasury Shares · Aug 25 - Material event report (treasury share disposal)
Genolution disclosed a plan to sell treasury shares worth US$89K, about 0.4% of its market value.
Treasury Shares · Aug 24 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Genolution updated its previously filed consolidated results for FY2025: revenue of US$6.37M (+31.8% year on year), an operating loss of US$5.86M and a net loss of US$8.53M.
Earnings · Mar 12 · 2 versions - Treasury share disposal: results reportTreasury Shares · Feb 20
- Change of largest shareholderOwnership change · Feb 19
- [Amended] Share transfer agreement that will change the largest shareholder
Genolution's controlling stake is now set to change hands from a company to an individual, in a deal worth US$1.02M.
Ownership change · Feb 19 · 2 versions - Material event report (treasury share disposal)
Genolution disclosed a plan to sell treasury shares worth US$13.4K, about 0.1% of its market value.
Treasury Shares · Feb 12